Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

11 november 2026 uppdaterad av: Kestrel Therapeutics, Inc.

A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.

Studieöversikt

Detaljerad beskrivning

This is a first-in-human, phase 1, open-label, multicenter clinical trial designed to evaluate safety, tolerability, pharmacokinetics, biomarkers, pharmacodynamics and preliminary activity of orally administered KST-6051 as monotherapy or in combination with other anticancer agents. The trial seeks to enroll adults with advanced or metastatic KRAS mutant solid tumors including but not limited to pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer whose cancers have progressed after prior therapy or in whom standard therapy was not tolerated. The trial includes a dose escalation phase in which higher doses of KST-6051 will be given in subsequent groups of participants. The trial also includes a dose expansion phase to further investigate KST-6051. Participants can stay in the trial as long as they benefit from the treatment and can tolerate it.

Studietyp

Interventionell

Inskrivning (Beräknad)

545

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90048
        • Rekrytering
        • Cedars-Sinai Medical Center
    • Florida
      • Sarasota, Florida, Förenta staterna, 34232
        • Rekrytering
        • Florida Cancer Specialists
      • Tampa, Florida, Förenta staterna, 33612
        • Rekrytering
        • Moffitt Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02114
        • Rekrytering
        • Mass General Brigham Cancer Institute at Massachusetts General Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Rekrytering
        • Sidney Kimmel Cancer Center
        • Kontakt:
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • The University of Texas MD Anderson Cancer Center
        • Kontakt:
      • San Antonio, Texas, Förenta staterna, 78229
        • Rekrytering
        • NEXT Oncology
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84112
        • Rekrytering
        • Huntsman Cancer Institute, University of Utah
        • Kontakt:
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Willing and able to give written informed consent.
  3. Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor.
  4. Documentation of KRAS mutation prior to the first dose of trial drug(s).
  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  6. Adequate cardiovascular, hematological, liver, and renal function.
  7. Measurable disease at baseline per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).

Exclusion Criteria:

  1. Central nervous system (CNS) tumors or untreated or unstable metastases.
  2. Inability to swallow oral medications.
  3. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial.

Other inclusion/exclusion criteria are specified in the protocol.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: KST-6051 Dose Escalation Monotherapy

Sequential cohorts with increasing doses of KST-6051 as monotherapy will be evaluated to determine recommended dose(s) for expansion (RDE[s]).

KST-6051 will be administered orally as a tablet.

Experimentell: KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel

Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of gemcitabine/nab-paclitaxel will be evaluated in participants with previously treated PDAC.

KST-6051 will be administered orally as a tablet.

Gemcitabine/nab-paclitaxel will be administered intravenously (IV).

Experimentell: KST-6051 Dose Escalation Combination Therapy with Cetuximab

Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of cetuximab will be evaluated in participants with previously treated KRAS-mutant mCRC.

KST-6051 will be administered orally as a tablet.

Cetuximab will be administered IV.

Experimentell: KST-6051 Dose Escalation Combination Therapy with Pembrolizumab

Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of pembrolizumab will be evaluated in participants with first- or second-line KRAS-mutant NSCLC.

KST-6051 will be administered orally as a tablet.

Pembrolizumab will be administered IV.

Experimentell: KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy

Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in PDAC after 1 or 2 prior lines of therapy.

KST-6051 will be administered orally as a tablet.

Experimentell: KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy

Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in mCRC after 1 or 2 prior lines of therapy.

KST-6051 will be administered orally as a tablet.

Experimentell: KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy

Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in NSCLC after 1 or 2 prior lines of therapy.

KST-6051 will be administered orally as a tablet.

Experimentell: KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors

Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in prior RAS/KRAS inhibitor-treated solid tumors.

KST-6051 will be administered orally as a tablet.

Experimentell: KST-6051 Dose Expansion Monotherapy in Later-line Settings

Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in selected KRAS-mutant biliary tract cancer, endometrial cancer (EC), or other solid tumors in later-line settings.

KST-6051 will be administered orally as a tablet.

Experimentell: KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel

Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with gemcitabine/nab-paclitaxel in 1L PDAC.

KST-6051 will be administered orally as a tablet.

Gemcitabine/nab-paclitaxel will be administered intravenously (IV).

Experimentell: KST-6051 Dose Expansion Combination Therapy with Cetuximab

Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab in 2L/3L CRC.

KST-6051 will be administered orally as a tablet.

Cetuximab will be administered IV.

Experimentell: KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI

Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab and mFOLFOX6 or FOLFIRI in 1L CRC.

KST-6051 will be administered orally as a tablet.

Cetuximab will be administered IV.

mFOLFOX6 will be administered IV.

FOLFIRI will be administered IV.

Experimentell: KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin

Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with pembrolizumab and pemetrexed/carboplatin in 1L NSCLC.

KST-6051 will be administered orally as a tablet.

Pembrolizumab will be administered IV.

Pemetrexed will be administered IV.

Carboplatin will be administered IV.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)
Tidsram: Up to Day 21 of Treatment Cycle 1
Up to Day 21 of Treatment Cycle 1
Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsram: Up to approximately 2 years

Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events.

Up to approximately 2 years
Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)
Tidsram: Up to approximately 2 years

Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events.

Up to approximately 2 years
Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR)
Tidsram: Up to approximately 2 years
Up to approximately 2 years

Sekundära resultatmått

Resultatmått
Tidsram
Dose Escalation Cohorts: Maximum Observed Blood Concentration (Cmax) of KST-6051 Alone
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: Cmax of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: Time to Achieve Cmax (Tmax) of KST-6051 Alone
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: Tmax of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: Half-life (t1/2) of KST-6051 Alone
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: t1/2 of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: Area Under the Blood Concentration-time Curve (AUC) of KST-6051 Alone
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: AUC of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
Up to Week 6
Dose Escalation Cohorts: ORR
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Disease Control Rate (DCR)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Duration of Overall Response (DOR)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Progression-free Survival (PFS)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Overall Survival (OS)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Escalation Cohorts: Duration of Stable Disease
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Expansion Cohorts: Time to Response (TTR)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Expansion Cohorts: Number of Participants With TEAEs
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Expansion Cohorts: Number of Participants with Dose Interruptions, Dose Reductions, and Discontinuations
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Expansion Cohorts: Relative Dose Intensity and Treatment Exposure
Tidsram: Up to approximately 2 years
Up to approximately 2 years
Dose Expansion Cohorts: Concentration of KST-6051 in the Whole Blood After Multiple Dose Administration
Tidsram: Up to Week 6
Up to Week 6

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

21 april 2026

Primärt slutförande (Beräknad)

1 april 2028

Avslutad studie (Beräknad)

1 april 2029

Studieregistreringsdatum

Först inskickad

3 mars 2026

Först inskickad som uppfyllde QC-kriterierna

3 mars 2026

Första postat (Faktisk)

9 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • KST-6051-101

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera